:

Understanding What are the clinical outcomes in elderly patients receiving agalsidase alfa treatment in the Fabry outcome survey?

According to research published in Molecular Genetics and Metabolism Reports, long-term agalsidase alfa treatment can provide renal, cardiac, and overall survival protection in Fabry disease. A specific analysis focusing on older adults provides further detail on **what are the clinical outcomes in elderly patients receiving agalsidase alfa treatment in the Fabry outcome survey?**